Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2024-03-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
关于股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations of the company Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the investigation and confirmation that no undisclosed material information exists that could have caused the stock price volatility. The document is a regulatory disclosure about stock trading behavior and compliance with information disclosure rules. It does not contain financial statements, earnings data, or detailed reports but is a formal announcement to the market about stock price abnormality and company investigation results. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report.
2024-03-14 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase program. It details the number of shares repurchased, prices, total amount spent, and compliance with regulatory requirements. It references previous announcements about the repurchase plan and provides updates on the ongoing buyback activity. The document is relatively short (1552 characters) and focuses on the status of the share repurchase, not on financial results or other report types. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers company buyback or sale of its own shares.
2024-03-04 Chinese
关于持股5%以上股东减持计划的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding a shareholder holding more than 5% of the company's shares planning to reduce their holdings. It details the shareholder's name, shareholding percentage, planned reduction amount, methods, timing, and legal compliance. There are no financial statements, earnings data, or management discussion of results. The document is a notification about a shareholding change plan, specifically a reduction in shares by a major shareholder. This fits the definition of a Major Shareholding Notification (MRQ). The document length is 2544 characters, which is typical for such announcements and not a full report or regulatory filing. Therefore, the classification is MRQ with high confidence.
2024-03-01 Chinese
关于首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's first share repurchase. It details the number of shares repurchased, prices, total amount spent, and compliance with relevant regulations. It references the company's share repurchase plan and previous announcements but does not contain financial statements or detailed financial analysis. The document is short (1483 characters) and serves as a disclosure of a specific transaction event rather than a full financial report or presentation. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers share buybacks or sales by the company itself.
2024-02-21 Chinese
回购报告书
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding a share repurchase plan. It includes specifics about the repurchase price range, total funds to be used, number of shares to be repurchased, purpose of the repurchase (for equity incentives or employee stock ownership plans), implementation period, risk warnings, and regulatory compliance. The document is titled '回购报告书' which translates to 'Repurchase Report' or 'Buyback Report'. It is not a financial report like an annual or interim report, nor is it a regulatory filing or announcement of a report publication. The content focuses on the company's share buyback plan and related details, which fits the category of Transaction in Own Shares (POS). The document length is 7679 characters, indicating it is a substantive report rather than a brief announcement. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2024-02-21 Chinese
关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the shareholding situation of the top ten shareholders and top ten unrestricted shareholders before a share repurchase decision by the company's board. It references a share repurchase plan approved on February 7, 2024, and provides detailed shareholding data as of February 8, 2024. The content focuses on shareholding details related to a share buyback, not on financial results, management changes, or voting outcomes. This fits the category of a Transaction in Own Shares (POS) report, which covers company buybacks or sales of its own shares. The document length is under 5,000 characters and contains detailed shareholding data relevant to the repurchase, confirming it is not merely an announcement of a report but a substantive disclosure about share transactions.
2024-02-21 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.